A scientist can design a genetic construct before lunch and spend the next several weeks waiting for the physical DNA to appear. The screen moves at software speed. The bench does not. Jason Gammack, the chief executive of Ansa Biotechnologies, has built his current chapter around the distance between those two clocks.
His proposition is almost aggressively practical. If Ansa accepts a synthetic DNA order under its guarantee, the complete order ships on the promised date or the customer does not pay. In a field fluent in breakthroughs, Gammack talks about broken promises. He wants a sophisticated biological input to behave like an ordinary reagent: chosen, ordered, received, used.
That sounds modest only if you ignore what comes next. A DNA construct may start an experiment, a screening campaign, a cell-engineering program, or a manufacturing study. When it arrives late, the delay travels downstream. People wait. Instruments sit. Plans are revised. A procurement failure quietly becomes a research failure.
“The constraints they've been taught to accept are not laws of nature. They're artifacts of legacy manufacturing.”Jason T. Gammack, 2026
The handoff
Gammack joined Ansa in February 2024, when the Emeryville company was leaving its early-access period and preparing a commercial service for complex clonal genes and fragments. The transition was explicit. Co-founder Dan Lin-Arlow moved from chief executive to chief scientific officer. Gammack became the first commercially focused CEO, responsible for turning a founder-built synthesis method into a business customers could rely on.
He brought an unusual kind of continuity. For more than 30 years, his work has sat near the tools that changed how researchers handle biological information. His résumé runs through Promega, Affymetrix, Invitrogen and Life Technologies, Sigma-Aldrich, Ingenuity Systems, QIAGEN, and Inscripta. The company names chart an industry moving from measuring biology toward manipulating it.
His education hints at the combination he would keep returning to: a B.S. from Iowa State University and a Ph.D. from the University of Washington, followed by a career spent largely on the commercial side of science. He learned the work between invention and adoption, where a product needs a clear use, a reachable customer, trained support, and an economic reason to change an established routine. By the time Ansa called, Gammack had seen that passage from nearly every angle: inside large suppliers, after an acquisition, at a gene-editing company opening a market, and as a founder asking investors and laboratories to believe in a new category.
Three verbs, one career
A commercial path through the changing toolkit of biology
The useful thread is not a single technology. It is the work of converting a technical platform into something a laboratory can adopt.
Context before code
Between gene editing and DNA writing came a founder's turn. In 2020, Gammack co-founded Resolve Biosciences with Axel Heinemann and Peer Schatz. Resolve's Molecular Cartography platform was built to measure molecular activity while preserving its position inside tissue. Gammack described the problem with an explanatory device: the genome is a book, and letters lose meaning when the reader cannot see their context.
He called the progression “Genomics 1.0,” “Genomics 2.0,” and “Genomics 3.0.” The first era established the ability to clone genes. The next brought massively scaled sequencing. The third, in his telling, restores the where: which molecular event happened in which cell, and where that cell sat. The language is revealing. Gammack is at ease turning a dense platform into a sequence a customer can repeat.
Resolve launched its first product, built a team across the United States and Germany, and raised a $71 million Series B in 2022. Gammack left during a CEO transition in 2023. The next year he arrived at Ansa, confronting the complementary side of the biology toolkit. Resolve helped researchers see biological context. Ansa would help them build what they had designed.
The factory is the argument
Traditional DNA synthesis relies on phosphoramidite chemistry developed decades ago. It is productive and deeply optimized, but long or awkward sequences can still force compromises. Repeats, high GC content, and secondary structures make some designs difficult to manufacture. Researchers learn to alter the sequence, assemble shorter pieces themselves, or send the same order to several vendors and hope.
Ansa's method uses an enzyme, terminal deoxynucleotidyl transferase, and enzyme-nucleotide conjugates to add bases. The company's manufacturing process combines synthesized fragments into larger, verified constructs. Its current clonal range runs from 100 base pairs to 50 kilobases. Gammack likes a physical analogy for the advantage: if you want to build a large Lego castle, start with large Lego pieces.
From fragment to construct
Two different product scales in Ansa's published range
The bars show scale, not identical workflows: the shorter figure is a directly synthesized DNA fragment; the 50 kb product is an assembled, sequence-verified clonal construct.
The company screens each submitted sequence and sorts it into one of three useful answers: guaranteed, let's try, or not currently possible. More than 90 percent of orders have fallen into the guaranteed category, according to Gammack. The middle group contains designs whose repeats or other features demand experimentation. The third group is small and often includes sequences that can be synthesized but not propagated in a cell as a clone.
This triage is an especially revealing part of the operating model. A guarantee is credible only if the seller knows when to withhold it. The system translates manufacturing knowledge into a clear promise before the customer has reorganized a project around an optimistic estimate.
“Scientists want to do top-of-the-spear science, not blocking and tackling.”Jason T. Gammack, 2025
What the guarantee changes
Laboratories already contain scientific uncertainty. Results fail. Hypotheses bend. Cells behave inconveniently. Gammack's point is that procurement uncertainty need not join the list. Ansa's guarantee moves some of that risk back to the manufacturer, the party with the process data and the ability to improve the process.
It also gives Ansa a demanding internal scoreboard. A complete-order promise is stricter than shipping the easy sequences first and leaving the difficult tail unresolved. Delivery performance becomes legible to the customer and expensive to the company when it misses. The marketing claim therefore doubles as an operating constraint.
A technical advantage becomes a product when the customer can build a schedule around it.
The commercial scaffolding has grown around that idea. In October 2025, Ansa announced a $54.4 million Series B to expand manufacturing. That same month it launched sequence-verified clonal DNA up to 50 kilobases, with the company describing delivery for ultra-long constructs in less than 25 days. In January 2026, Integrated DNA Technologies agreed to offer Ansa's clonal and XL clonal products to its customers, pairing Ansa's manufacturing with a distribution name familiar to research labs.
Beyond the inherited ceiling
Gammack's public ambition is larger than winning difficult orders. He argues that scientists have internalized the limits of their suppliers. If a vendor cannot make a long repeat or a complex promoter, the design is softened before it is tested. Over time, the manufacturing boundary begins to look like a biological boundary.
That is why his “artifacts” line lands. It invites researchers to reopen decisions that once appeared settled. What would they design if length, sequence complexity, and delivery time stopped dominating the brief? The answer might be a more faithful disease model, a larger engineered pathway, an ambitious vaccine construct, or an experiment that has no name yet. Gammack does not need to predict the winning application. A tools company succeeds by giving many researchers room to discover it.
His own career makes the position credible without making it inevitable. He has watched successive platforms arrive with expansive scientific promise and a stubborn commercial question: can a customer use this reliably? At Resolve, context was the missing layer around genomic data. At Ansa, the missing layer around synthetic DNA is confidence.
The beard and blunt copy make Gammack easy to remember on a conference program. The more durable signature is his insistence on customer language. He talks about the order, the date, the whole shipment, the next experiment. These are small nouns compared with synthetic genomes and programmable biology. They are also where a platform meets reality.
Modern biology will keep producing dazzling designs. Ansa's bet is that the less dazzling discipline of manufacturing will decide how many escape the screen. Gammack has made the calendar part of the product. If the model works, the most meaningful change will be quiet: scientists will order DNA, mark a date, and get on with the work they meant to do.